Article info
PDFClinical and epidemiological research
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
- Professor J Smolen, Division of Rheumatology, Medical University of Vienna, Vienna A-1090, Austria; josef.smolen{at}meduniwien.ac.at
Citation
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
Publication history
- Accepted October 28, 2008
- First published November 17, 2008.
Online issue publication
March 09, 2023
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Web only appendix for 68;6:797-804
Files in this Data Supplement:
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Smolen et al 2009 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.